Insurance companies resist covering RSV vaccine for newborns in hospitals

Insurance companies are increasingly refusing to cover the cost of RSV immunization for newborns administered during hospital stays, raising concerns about equitable access to the preventive treatment.

Respiratory syncytial virus, a common respiratory illness that can be severe in infants, has recently seen new immunization options introduced to market. However, insurers have begun denying claims for these vaccines when given in hospital settings, citing coverage limitations and reimbursement disputes.

The resistance from health insurers threatens to create a two-tiered system where access to RSV protection depends on a family's insurance status and ability to pay out-of-pocket. Medical professionals have emphasized that early immunization during hospital stays offers critical protection for newborns during their most vulnerable months.

Healthcare providers and patient advocates are working to address the coverage disputes, arguing that preventing severe RSV infection in infants produces significant long-term health and economic benefits. Insurance industry representatives have suggested concerns about cost containment and the need for clearer clinical guidelines on vaccine administration.

Photo: Scanning electron micrograph of human respiratory syncytial virus (RSV) particles. NIAID via Wikimedia Commons (CC BY 2.0).